Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sanofi Invests in Graviton and its Lead Product, a ROCK2 Inhibitor in-licensed from Beijing Tide

publication date: Feb 1, 2024

Sanofi, a Paris multinational biopharma focused on novel drugs and vaccines, made an unspecified investment in New York City’s Graviton Bioscience in return for a 12-month right-of-first-refusal to acquire global rights to Graviton’s lead product, a ROCK2 inhibitor. Two years ago, Graviton acquired global (ex-China) rights to the candidate from Beijing Tide Pharma, a Sinopharm subsidiary, in a $518 million deal. Graviton’s GV101 is a selective inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), currently in a Phase I trial. GV101 showed blood-brain-barrier penetration in preclinical tests, and Graviton believes it has best-in-class potential. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here